Literature DB >> 18685029

Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition.

Cinzia Costa1, Vincenzo Belcastro, Alessandro Tozzi, Massimiliano Di Filippo, Michela Tantucci, Sabrina Siliquini, Alessia Autuori, Barbara Picconi, Maria Grazia Spillantini, Ernesto Fedele, Anna Pittaluga, Maurizio Raiteri, Paolo Calabresi.   

Abstract

Reduced activity of the mitochondrial respiratory chain and in particular of complex I is implicated not only in the etiology of Parkinson's disease but also in other forms of parkinsonism in which striatal neurodegeneration occurs, such as progressive supranuclear palsy. The pesticide rotenone inhibits mitochondrial complex I and reproduces features of these basal ganglia neurological disorders in animal models. We have characterized the electrophysiological effects of rotenone in the striatum as well as potential neuroprotective strategies to counteract the detrimental effects of this neurotoxin. We found that rotenone causes a dose-dependent and irreversible loss of the corticostriatal field potential amplitude, which was related to the development of a membrane depolarization/inward current in striatal spiny neurons, coupled to an increased release of both excitatory amino acids and dopamine (DA). In particular, we have investigated whether glutamate, DA, and GABA systems might represent possible targets for neuroprotection against rotenone-induced striatal neuronal dysfunction. Interestingly, whereas modulation of glutamatergic transmission was not neuroprotective, blockade of D(2)-like but not D(1)-like DA receptors significantly reduced the rotenone-induced effects via a GABA-mediated mechanism. In addition, because antiepileptic drugs (AEDs) modulate multiple transmitter systems, we have analyzed the possible neuroprotective effects of some AEDs against rotenone. We found that carbamazepine, unlike other tested AEDs, exerts a potent neuroprotective action against rotenone-induced striatal neuronal dysfunction. This neuroprotection was observed at therapeutically relevant concentrations requiring endogenous GABA. Differential targeting of GABAergic transmission may represent a possible therapeutic strategy against basal ganglia neurodegenerative disorders involving mitochondrial complex I dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685029      PMCID: PMC6670775          DOI: 10.1523/JNEUROSCI.1947-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  21 in total

1.  Mitochondrial CB₁ receptors regulate neuronal energy metabolism.

Authors:  Giovanni Bénard; Federico Massa; Nagore Puente; Joana Lourenço; Luigi Bellocchio; Edgar Soria-Gómez; Isabel Matias; Anna Delamarre; Mathilde Metna-Laurent; Astrid Cannich; Etienne Hebert-Chatelain; Christophe Mulle; Silvia Ortega-Gutiérrez; Mar Martín-Fontecha; Matthias Klugmann; Stephan Guggenhuber; Beat Lutz; Jürg Gertsch; Francis Chaouloff; María Luz López-Rodríguez; Pedro Grandes; Rodrigue Rossignol; Giovanni Marsicano
Journal:  Nat Neurosci       Date:  2012-03-04       Impact factor: 24.884

2.  Protective effect of carbamazepine on kainic acid-induced neuronal cell death through activation of signal transducer and activator of transcription-3.

Authors:  Hae Jeong Park; Su Kang Kim; Joo-Ho Chung; Jong Woo Kim
Journal:  J Mol Neurosci       Date:  2012-07-08       Impact factor: 3.444

Review 3.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

4.  Acute exposure to the mitochondrial complex I toxin rotenone impairs synaptic long-term potentiation in rat hippocampal slices.

Authors:  Ryoichi Kimura; Lu-Yao Ma; Chen Wu; Dharshaun Turner; Jian-Xin Shen; Kevin Ellsworth; Makoto Wakui; Marwan Maalouf; Jie Wu
Journal:  CNS Neurosci Ther       Date:  2012-05-22       Impact factor: 5.243

5.  In vitro effects of antidepressants and mood-stabilizing drugs on cell energy metabolism.

Authors:  Tereza Cikánková; Zdeněk Fišar; Jana Hroudová
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-19       Impact factor: 3.000

6.  Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson's disease.

Authors:  K M Denny Joseph
Journal:  Neurochem Res       Date:  2015-02-17       Impact factor: 3.996

7.  Effect of temperature on FAD and NADH-derived signals and neurometabolic coupling in the mouse auditory and motor cortex.

Authors:  Baher A Ibrahim; Huan Wang; Alexandria M H Lesicko; Bethany Bucci; Kush Paul; Daniel A Llano
Journal:  Pflugers Arch       Date:  2017-08-07       Impact factor: 3.657

8.  Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.

Authors:  L V Darbinyan; L E Hambardzumyan; K V Simonyan; V A Chavushyan; L P Manukyan; S A Badalyan; N Khalaji; V H Sarkisian
Journal:  Metab Brain Dis       Date:  2017-07-10       Impact factor: 3.584

9.  A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

Authors:  Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; Birgit Liss; Javier Fernández-Ruiz; Manfred Gerlach; Ullrich Wüllner; Hartmut Lüddens; Paolo Calabresi; Georg Auburger; Suzana Gispert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

10.  Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.

Authors:  S Arpin; E Lagrue; S Bodard; S Chalon; P Castelnau
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.